REGENERON

Regeneron Pharmaceuticals, Inc.
Investor Relations Department
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States

Visit IR website
Sign-up for email alerts

NASDAQ: REGN [1]	
Last Trade:	254.87
Trade Time:	4:15 PM ET May 23, 2013
Change:	-7.55 (2.877%)
Day Range	245.52 - 260.47
52-Week Range	107.31 - 283.99
Volume	845,300
Market Cap. ($M)	24,444.072
Shares Out (M)	95.908

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Welcome to the Investor Relations page. If you are a member of the investment community with a question about Regeneron, please call our Investor Relations Line at (914) 345-7400.

For an e-mail response to your Regeneron investment question, please contact us at invest@regeneron.com.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, age-related macular degeneration, and certain cancers. Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic conditions, and cancer.

… (more)

Stock Performance



Press Releases [View all]

May 21, 2013
Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine

May 15, 2013
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)

May 8, 2013
Regeneron Announces Upcoming 2013 Investor Conference Presentations

May 3, 2013
Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs

May 3, 2013
Regeneron Reports First Quarter 2013 Financial and Operating Results

Events [View all]

May 29, 2013 8:40 AM ET
38th Annual dbAccess Healthcare Conference

Jun 3, 2013 9:00 AM ET
Jefferies 2013 Healthcare Conference

Financials [View all]

Fourth Quarter Financial Results

Feb 15, 2013
Annual Report (10-K)

Apr 29, 2013
Definitive Proxy Statement

May 3, 2013
Quarterly Report (10-Q)

Oct 24, 2012
Quarterly Report (10-Q)

Jul 25, 2012
Quarterly Report (10-Q)

NASDAQ OMX